Remote Ischemic Conditioning (RIC)

Has been shown to significantly reduce Ischemia Reperfusion Injury (IRI) caused by cardiac events or cardiac intervention






Learn more about RIC
The autoRIC™ Device

Automates RIC provides
Safe, Convenient and Accurate therapy delivery

Approved for use in Canada and EU

CAUTION: Investigational Device. Limited by United States law to Investigational Use.

Discover the autoRIC™ Device
RIC Clinical Research Trials

Over 100 completed and ongoing trials with more than 20,000 patients world-wide, zero adverse events reported









View RIC Clinical Trials
RIC Markets

$2 Billion Acute Market: Hospital and pre-hospital settings
$4-6 Billion Chronic Market: Heart Failure, Stroke, Home & Public settings








Explore RIC Markets

CellAegis Devices Inc. - Media Coverage

May 2, 2014 - Medical device developed by SickKids doctors named as a top game-changer

The science behind the CellAegis autoRIC™ Device System has been selected as one of Canada‚Äôs top 10 game-changing health technologies by The Canadian Network for Environmental Scanning in Health at the 2014 Canadian Agency for Drugs and Technologies in Health Symposium in April. CellAegis has exclusive rights to the technology developed at Sick Kids.


CellAegis Devices: 2012 Mind to Market Award Finalist

CellAegis autoRIC™ Device
European Hospital Early Adopter Program


Safe for your patient, Simple for you!
Preferred Consumables Pricing
Capital Costs Eliminated
Three-year warranty on Device(s)

Better Cath Lab Outcomes, Improved Clinical Benefit
pPCI: Infarct size reduction, MACE & mortality reduced
ePCI: Troponin and MACCE reductions
Coronary Angiogram/TAVR: Significant reduction in CI-AKI

For more information about the autoRIC™ Device or to inquire about our European Hospital Early Adopter Program:

Call us: 1-647-722-9601 Email us: info@cellaegisdevices.com